Tempest Therapeutics (NASDAQ:TPST) Posts Earnings Results, Misses Expectations By $2.25 EPS

Tempest Therapeutics (NASDAQ:TPST) posted its quarterly earnings data on Thursday. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25), FiscalAI reports.

Tempest Therapeutics Trading Up 13.6%

NASDAQ TPST traded up $0.25 on Thursday, reaching $2.09. 252,668 shares of the company were exchanged, compared to its average volume of 176,203. The business’s fifty day moving average price is $1.96 and its 200 day moving average price is $3.42. The stock has a market capitalization of $29.98 million, a P/E ratio of -0.31 and a beta of -1.75. Tempest Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $12.23.

Analyst Upgrades and Downgrades

Several analysts recently commented on TPST shares. Zacks Research upgraded Tempest Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 2nd. Wall Street Zen upgraded Tempest Therapeutics to a “hold” rating in a research report on Saturday, April 18th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

Insiders Place Their Bets

In related news, CEO Matthew Angel acquired 231,482 shares of the stock in a transaction on Tuesday, March 24th. The shares were bought at an average price of $2.16 per share, with a total value of $500,001.12. Following the completion of the purchase, the chief executive officer owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.28% of the company’s stock.

Hedge Funds Weigh In On Tempest Therapeutics

A hedge fund recently bought a new stake in Tempest Therapeutics stock. Dimensional Fund Advisors LP purchased a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 11,444 shares of the company’s stock, valued at approximately $33,000. Dimensional Fund Advisors LP owned about 0.23% of Tempest Therapeutics as of its most recent SEC filing. 22.52% of the stock is owned by institutional investors.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.